

# Abbreviations - NAMS Roadmap (2023)

## In this guide

### [In this guide](#)

1. [Cover - NAMS Roadmap \(2023\)](#)
2. [Executive summary - NAMS Roadmap \(2023\)](#)
3. [Introduction & Background NAMs Roadmap Draft Version 3 \(2023\)](#)
4. [What are NAMs and why is there a drive in the regulatory context? - NAMS Roadmap \(2023\)](#)
5. [Who are the UK FSA and the COT? - NAMS Roadmap \(2023\)](#)
6. [Worldwide perspectives on emerging technologies - NAMS Roadmap \(2023\)](#)
7. [UK Government cross cutting themes on NAMS, data and emerging technologies - NAMS Roadmap \(2023\)](#)
8. [Future Government cross themes - NAMS Roadmap \(2023\)](#)
9. [What have the FSA/COT done so far? - NAMS Roadmap \(2023\)](#)
10. [Exploring Dose Response \(EDR\) Workshop Summary - NAMS Roadmap \(2023\)](#)
11. [PBPK for Regulators Workshop Summary - NAMS Roadmap \(2023\)](#)
12. [The proposal: How does the FSA plan to integrate NAMs in the regulatory space? - NAMS Roadmap \(2023\)](#)
13. [The 7 Steps to Integration & Acceptance - NAMS Roadmap \(2023\)](#)
14. [Future Visions: The new normal chemical landscape - NAMS Roadmap \(2023\)](#)
15. [References - NAMS Roadmap \(2023\)](#)
16. [Abbreviations - NAMS Roadmap \(2023\)](#)
17. [Technical information - NAMS Roadmap \(2023\)](#)
18. [Acknowledgments - NAMS Roadmap \(2023\)](#)
19. [More information - NAMS Roadmap \(2023\)](#)

**3Rs**

Replacement, Reduction and Refinement

**4IR**

4th industrial revolution

<b>AI</b>	Artificial Intelligence
<b>AOPs</b>	Adverse outcome pathways
<b>ARIs</b>	Areas of Research Interest
<b>COC</b>	Committee on Carcinogenicity
<b>COT</b>	Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment
<b>DALYs</b>	Disability-adjusted life years
<b>FSA</b>	Food Standards Agency
<b>HTS</b>	High Throughput Screening
<b>IATAs</b>	Integrated approaches to testing and assessment
<b>NC3Rs</b>	National Centre for the Replacement, Refinement and Reduction of Animal Research
<b>NAMs</b>	New Approach Methodologies
<b>PBPK</b>	Physiologically based pharmacokinetics
<b>PODs</b>	Points of departure

<b>SETE</b>	Synthesis and Integration of Epidemiological and Toxicological Evidence Subgroup
<b>SERD</b>	Science, Evidence and Research Division
<b>UKHSA</b>	UK Health Security Agency
<b>QALY</b>	Quality Adjusted Life Year
<b>QSAR</b>	Quantitative structure Activity Relationships
<b>VOLY</b>	Value of Life Year